Post-earnings recap
Reported
Tue, May 5, 2026
EPS actual
$-1.67
EPS est.
$-1.67
EPS surprise
-0.18%
1-day move
+16.71%
Cytokinetics reported a wider loss than expected for the first quarter of 2026, which typically might concern investors. However, the stock surged by 16.71%, indicating that investors may be optimistic about future developments or other underlying factors not captured in the earnings report. The lack of revenue data could also mean that investors are focusing on other aspects of the company's potential.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.67 | $-1.65 | -0.18% |
| Revenue | — | $9M | — |
No transcript is on record, and the analysis is based on numerical results only.
Cytokinetics, Incorporated is a biotechnology company focused on developing treatments for serious diseases related to muscle function. With a market cap of $8 billion, it plays a significant role in the health care sector, particularly in addressing conditions that affect muscle strength and mobility.
Last quarter
In Q4-2025, Cytokinetics reported an EPS of $-1.50, slightly missing expectations, which led to a modest stock increase of 2.70% the following day. The company continues to navigate challenges in revenue generation.
EPS beat streak
1Q
EPS beat rate
38%
Avg EPS surprise
-5.68%
Avg 1-day reaction
+2.72%
Analysts expect Cytokinetics to report a loss this quarter, with a consensus EPS of $-1.65 and revenue of $9 million. Investors are particularly focused on how the company manages its costs and revenue growth.
Bull case
If Cytokinetics can exceed revenue expectations and show signs of improved cost management, it could signal a turnaround in its financial performance, leading to a positive stock reaction.
Bear case
Conversely, if the company fails to meet revenue expectations or reports higher losses than anticipated, it may lead to a significant decline in stock price.
Key metrics to watch
EPS
$-1.65Earnings per share is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue
$9MRevenue figures help gauge the company's ability to generate sales and are crucial for assessing growth potential.
The print will turn on these.
Q1
Will Cytokinetics achieve revenue of at least $9 million this quarter?
Meeting or exceeding this revenue target is crucial for demonstrating growth and attracting investor confidence.
Q2
What specific strategies is management implementing to reduce losses this quarter?
Investors will be keen to understand how the company plans to manage costs and improve its financial outlook.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The market may be underestimating Cytokinetics' potential for revenue growth, especially given recent advancements in their product pipeline.
Supporting evidence
The options market is pricing in a 44.97% move, indicating expectations for significant volatility that may not align with historical performance.
Cytokinetics has a history of surprising analysts, as seen in previous quarters where they exceeded EPS expectations despite losses.
Key risk
If revenue comes in significantly above the $9 million consensus, it could shift market sentiment dramatically.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it will reflect the company's ability to stabilize its financial situation after recent challenges.
Bull confirmed if
Achieving revenue above $9 million would confirm the bull case and suggest a positive trend in sales.
Bear confirmed if
Reporting revenue below $4 million would confirm the bear case and raise concerns about the company's viability.
What the market is pricing for the move.
Implied Move
±44.97%
Historical Avg
±4.7%
The options market is pricing in a significant potential move in the stock, indicating that investors are anticipating volatility around the earnings report.
Options are pricing ±43.0% while CYTK has averaged ±4.7% over the last 8 prints — setup is pricing rich.
ATM IV
2.7%
30d HV
39.8%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$705,780.00
11,000 sh
2 insiders
Net
$705,780.00
Net selling
Most Active Insiders· 2 open-market trades
$490,950.00
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
125.94%
of float
Insider
0.64%
of float
Holders
657
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
20,094,362 sh · $1.2B
16.15%
21.4%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Cytokinetics beats expectations, history suggests the stock could rise by an average of 2.39%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await further clarity from management.
Miss
Should the company miss expectations, history suggests a potential decline of around 2.39%, which could heighten concerns about its financial health.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
1 buy·0 sells
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
$214,830.00
Net selling
Recent Transactions
Sep 28, 2026 · @ $65.46
7,500 sh
$490,950.00
Oct 6, 2026 · @ $61.38
3,500 sh
$214,830.00
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
T. Rowe Price Investment Management, Inc.
18,718,498 sh · $1.1B
15.04%
6.8%
Wellington Management Group, LLP
6,931,770 sh · $423.7M
5.57%
-13.5%
Vanguard Portfolio Management LLC
6,711,799 sh · $410.2M
5.39%
14.9%
State Street Corporation
6,494,233 sh · $396.9M
5.22%
13.0%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net buying
Recent Transactions
Traded Jun 30, 2026 · disclosed Jul 2, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.